GLP-1 NAION Vision Loss Lawsuit
Were you diagnosed with NAION or experienced sudden vision loss, after using any of these GLP-1 medications: Ozempic, Trulicity, Wegovy, Saxenda, Victoza, Mounjaro, Rybelsus or Zepbound?
You may be eligible for compensation
- July 13, 2025
- Written By Attorney Troy Bouk
Bouk Law PLLC is actively reviewing claims on behalf of individuals who suffered a sudden loss of vision after taking GLP-1 medications.
If you used any of these GLP-1 medications (Ozempic, Trulicity, Wegovy, Saxenda, Victoza, Mounjaro, Rybelsus or Zepbound) and were later diagnosed with NAION or experienced sudden vision loss in one eye you may be eligible for compensation.
NAION Vision Loss Lawsuit Information On This Page...
What is NAION?
Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition characterized by sudden, painless vision loss in one eye due to reduced blood flow to the optic nerve. NAION is considered the most common optic nerve-related cause of sudden vision loss in older adults and can lead to partial or complete, permanent vision impairment.
What are the Symptoms of NAION Vision Loss?
Symptoms of NAION may include:
- Sudden vision loss in one eye, often noticed upon waking
- Blurry or dim vision
- Loss of visual field, typically in the upper or lower half
- Decreased color perception
- A pale, swollen optic disc visible during eye exam
What medications contain GLP-1?
GLP-1 medications include the following brand-name drugs:
- Ozempic
- Trulicity
- Wegovy
- Saxenda
- Victoza
- Mounjaro
- Rybelsus
- Zepbound
Who manufactures GLP-1 medications?
- Novo Nordisk manufactures Ozempic, Wegovy, Saxenda, Victoza, and Rybelsus.
- Eli Lilly & Company manufactures Trulicity, Mounjaro, and Zepbound.
What are GLP-1 medications used to treat?
GLP-1 receptor agonists are used primarily to treat:
- Type 2 diabetes, by improving blood sugar control
- Obesity, by promoting weight loss through appetite regulation and slowed gastric emptying
What studies have linked GLP-1 to developing NAION?
Several recent studies have raised concern about a possible association between GLP-1 medications and NAION:
China Medical University Hospital (May 2025)
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes. JAMA Ophthalmology (2025)
- This was a cohort study of 3,344,205 patients with diabetes.
- Those taking semaglutide were found to have an increased risk for NAION at the 2-year (HR, 2.39; 95% CI, 1.37-4.18), 3-year (HR, 2.44; 95% CI, 1.44-4.12), and 4-year (HR, 2.05; 95% CI, 1.26-3.34) time points from the index date.
- Increased risk for NAION was also noted in patients with diabetes and concomitant hypertension who were taking semaglutide (HR, 2.42; 95% CI, 1.19-4.92).
- An increased NAION risk was also observed among patients with diabetes who had a history of Ozempic (Novo Nordisk) use or stand-alone Ozempic (Novo Nordisk) prescription history.
BMC Ophthalmol. (March, 2025).
- Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association. BMC Ophthalmol (2025).
JAMA Case Series Study (January, 2025)
- Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide. JAMA Ophthalmol (2025).
Danish Nationwide Study (December 2024)
- Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes, International Journal of Retina and Vitreous (2024).
Harvard Medical School Study (August, 2024)
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide, JAMA Ophthalmology (2024)
- This matched cohort study of 16,827 patients revealed higher risk of NAION in patients prescribed semaglutide compared with patients prescribed non–glucagon-like peptide receptor agonist medications for diabetes or obesity. A Cox proportional hazards regression model showed a higher risk of NAION for patients prescribed semaglutide (HR, 7.64; 95% CI, 2.21-26.36; P < .001).
Have any government agencies linked NAION to GLP-1 medications?
As of mid-2025, the FDA has not issued a formal warning linking GLP-1 medications to NAION. However, regulators are actively reviewing post-marketing surveillance data.
Is NAION a permanent injury or can it be reversed?
Unfortunately, NAION is usually a permanent condition. Once the optic nerve is damaged due to ischemia, the lost vision does not typically recover.
What treatment options are available to treat NAION?
There is no established cure for NAION. However, treatment options may include managing risk factors, corticosteroids in some cases, low vision aids, and experimental therapies under investigation.
Is there a particular dosage of GLP-1 that is more susceptible to causing NAION?
Current studies have not identified a definitive dose-dependent relationship. However, some case reports suggest that higher doses used for weight loss may pose a greater risk.
Which active ingredients in GLP-1 medications appear more or less susceptible to causing NAION?
Preliminary data suggest that semaglutide and liraglutide may have a stronger correlation with NAION cases. Dulaglutide and tirzepatide are also under investigation, but fewer NAION cases have been publicly reported so far.
How many people in the United States are diagnosed with NAION each year?
NAION affects approximately 6,000 to 10,000 Americans annually. It is the most common optic neuropathy in adults over the age of 50.
Has the number of people diagnosed with NAION been increasing each year?
Some specialists have reported an uptick in younger patients experiencing NAION, coinciding with the rise in GLP-1 prescriptions for weight loss.
How does GLP-1 treat type 2 diabetes?
GLP-1 receptor agonists help manage type 2 diabetes by increasing insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety.
How does GLP-1 treat weight loss?
GLP-1 medications contribute to weight loss by delaying stomach emptying, suppressing appetite, and reducing food cravings and caloric intake.
Who may be eligible for compensation?
People who used GLP-1 medications and were diagnosed with NAION or experienced sudden vision loss may be eligible for compensation.
The following brand names are GLP-1 medications: Ozempic, Trulicity, Wegovy, Saxenda, Victoza, Mounjaro, Rybelsus, Zepbound.
Should I stop taking my GLP-1 medication?
Do not stop taking a prescribed medication without first consulting with your doctor.
What is the current status of the GLP-1 NAION Vision Loss litigation?
Claims are currently being filed in State and Federal Courts around the country.
How much does a lawyer cost?
At Bouk Law, we represent NAION injury clients on a contingency fee basis. That means:
- No upfront costs
- You pay nothing unless we recover compensation for you
Why Choose Bouk Law?
✅ We handle mass tort claims nationwide
✅ You speak directly with experienced attorneys
✅ You pay nothing unless we recover compensation
✅ We treat every case with care and urgency